Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: An open trial.
BACKGROUND
Oral lichen planus is chronic and can be debilitating. Topical corticosteroids are most frequently used for treatment, but they are not always effective.


OBJECTIVE
Hydroxychloroquine sulfate (Plaquenil), an antimalarial agent, was evaluated in an open trial (10 patients) for its ability to improve oral lichen planus.


METHODS
Patients received hydroxychloroquine, 200 to 400 mg daily, as a monotherapy for 6 months. Patients were assessed at baseline and every 4 to 8 weeks during treatment. Baseline ophthalmologic examinations were performed, and laboratory values were monitored before and during treatment.


RESULTS
Nine of ten patients had an excellent response to therapy. Three of six patients with erosions at baseline had complete healing. Pain relief and reduced erythema were usually observed after 1 to 2 months of therapy, but erosions required 3 to 6 months of treatment before they resolved. There were no adverse effects.


CONCLUSIONS
Hydroxychloroquine may be useful in the treatment of oral lichen planus.
Eisen
D
D
Dermatology Associates of Cincinnati, Inc., OH 45230.
D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000008:administration & dosage / Q000627:therapeutic use*; D008010:Lichen Planus / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy*; D012074:Remission Induction; D013997:Time Factors; D014945:Wound Healing
D006886:Hydroxychloroquine